Altasciences
- Company typePrivate
- Founded1995
- HeadquartersLaval, Canada
- Headcount251–500
- GTM typeB2B
- OfferingServices
Altasciences firmographics
Firmographics- Name
- Altasciences
- Legal name
- Altasciences
- Website
- https://altasciences.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Altasciences industry classification
Industry- Product category
- Contract Research Organization (CRO) and CDMO Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Testing Laboratories and Services (54138), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
Keywords
Where Altasciences is headquartered
LocationHeadquarters
- HQ city
- Laval
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Altasciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Preclinical Services: Contract research services for preclinical safety evaluation including GLP and non-GLP toxicology studies, safety pharmacology, pharmacokinetics/pharmacodynamics, and specialized preclinical studies across multiple species for small and large molecules.
- Clinical Research Services: Clinical pharmacology trials from first-in-human through Phase II, including proof-of-concept studies, bioavailability/bioequivalence, specialized assessments (CNS, topical, inhalation), and NDA-enabling studies conducted across three clinical pharmacology units with 580+ beds.
- Bioanalytical Services: Bioanalytical method development and validation, LC-MS/MS analysis, ligand binding assays, immunogenicity testing, biomarker analysis, flow cytometry, and sample management services supporting preclinical through Phase IV studies.
- Manufacturing and Analytical Services (CDMO): Pharmaceutical contract development and manufacturing including formulation development, clinical supply manufacturing (Phase I-III), commercial manufacturing, ICH stability testing, analytical method development and validation, and finished product release testing.
- Research Support Services: Complementary CRO services including regulatory affairs, biostatistics, data management, medical writing, clinical monitoring, project management, and program management to support integrated drug development programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom per-study or program-based pricing for integrated drug development services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Altasciences product offering
Product offeringCore offering
Altasciences is an integrated early-phase contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology (Phase I to Phase II), bioanalysis, research support services, and manufacturing and analytical services under a single integrated Acceleration Platform that reduces program timelines by up to 40%.
Product overview
Altasciences is an integrated early-phase contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering comprehensive drug development services. The company operates as a unified platform combining multiple service modules: Preclinical Services for safety assessment, Clinical Services for Phase I-II trials, Manufacturing and Analytical Services for pharmaceutical development, Bioanalytical Services for laboratory analysis, and Research Support Services for clinical operations. The Acceleration Platform serves as the core integrating architecture, enabling seamless transitions between preclinical through proof-of-concept phases. Additional specialized offerings include CNS Clinical Trials, Topical/Transdermal Studies, Inhalation Studies, Pain Models, PBMC Isolation, and Cell and Gene Therapy Development. The company's Tell Us Once commitment and dedicated Program Management services connect these modules to deliver end-to-end drug development with a single partner approach.
Differentiator
Problem solved
Functional benefit
Products and services
- Preclinical Services
- Clinical Services
- Manufacturing and Analytical Services
- Bioanalytical Services
- Research Support Services
- Cell and Gene Therapy Development
- CNS Clinical Trials
- Topical and Transdermal Studies
- Inhalation Studies
Quantifiable outcome
- 24% of all 2025 FDA novel drug approvals (11 of 46) supported by Altasciences' integrated approach
- +5 more outcomes
Companies that use Altasciences
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles3 records
Altasciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature11 records
Altasciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- CertaracoreStrategic partnership to integrate Certara's biosimulation technology and model-informed drug development (MIDD) services with Altasciences' drug development Acceleration Platform. The collaboration aims to help biotech sponsors establish proof of mechanism earlier, optimize study designs, and make more informed go/no-go decisions, addressing the industry challenge where fewer than half of preclinical candidates reach first-in-human trials. The partnership aligns with FDA's advancing guidance supporting adaptive, data-driven drug development approaches.
- VoxCell BioInnovationcoreStrategic collaboration to leverage VoxCell's 3D bioprinting and human-like tissue modeling technology to enhance preclinical research and accelerate drug development timelines. The partnership initially focuses on drug screening for ocular indications before expanding to other therapeutic areas. Both companies aim to reduce translational gaps and offer more predictive preclinical testing environments to pharmaceutical and biotechnology clients.
- Cambridge CognitioncorePartnership with Cambridge Cognition, a global leader in digital neuroscience technology, to deliver validated, non-invasive cognitive test batteries for CNS clinical trials. The partnership provides access to validated cognitive assessment tools covering attention, memory, executive function, and psychomotor performance for strategic cognitive testing in first-in-human and proof-of-concept studies.
- Cognitive Research Corporation (CRC)corePartnership with Cognitive Research Corporation (CRC) offering state-of-the-art driving simulation studies through Altasciences' 12 on-site driving simulators. The partnership provides accurate, reproducible data comparable in sensitivity to on-road testing for assessing drug effects on real-world driving performance, enabling sponsors to evaluate CNS-active compounds' impact on driving ability.
- Steel TherapeuticsminorSelected by Steel Therapeutics to conduct a pivotal toxicology study for Fizurex™, a topical therapy for anal fissures, at Altasciences' facility in Missouri. The study supports Steel's effort to seek regulatory approval for Fizurex™ with an IND application planned for early 2026.
Scale indicators12 records
Recent moves10 records
Expansion highlights6 records
Altasciences competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec: Global CRO/CDMO with end-to-end discovery, preclinical, clinical, and manufacturing services, often viewed as a comparable integrated platform, though at significantly larger scale and with a broader geographic footprint.
- ICON plc: Major global CRO offering clinical and bioanalytical services spanning Phase I-IV, directly competing for biotech and pharma early-phase work as part of a much broader services portfolio.
- IQVIA: Largest full-service CRO with deep clinical, real-world evidence, and technology capabilities; overlaps with Altasciences in early-phase clinical pharmacology and bioanalysis but operates as a broad incumbent across the entire drug development lifecycle.
- Syneos Health: Large clinical and commercial CRO with Phase I-IV capabilities, competing for early-phase engagements and providing a benchmark for mid-to-large CRO operating models.
- Parexel: Large global CRO providing Phase I-IV clinical, biostatistics, and regulatory services, overlapping with Altasciences in early-phase clinical pharmacology and bioanalytical work for biotech sponsors.
- Labcorp (Covance): Diversified clinical and preclinical CRO plus central laboratory, competing with Altasciences in early-phase clinical, bioanalytical, and central lab services for global biopharma sponsors.
Direct peers
- Worldwide Clinical Trials: Mid-size CRO with comparable early-phase clinical pharmacology capabilities and CNS expertise, competing head-to-head for the same biotech sponsor relationships.
- Medpace: Mid-size full-service CRO with strong mid-cap biotech focus and a tightly integrated operating model, often cited alongside Altasciences as a differentiated mid-size competitor in early- and mid-phase clinical work.
- BioAgilytix Labs: Specialized bioanalytical CRO supporting large-molecule PK, immunogenicity, and biomarker work, directly comparable to Altasciences' 685+ assay bioanalytical platform serving similar biotech and pharma sponsors.
- Charles River Laboratories: Direct peer in preclinical safety assessment and early-stage drug development, with a comparable end-to-end offering from preclinical through manufacturing, competing for the same biotech and pharma sponsors in North America and globally.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Altasciences social profiles
Digital presenceAltasciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altasciences leadership team
Management profileNumber of profiles
Profiles9 records
Altasciences subsidiaries and ownership
Company hierarchySubsidiaries2 records
Altasciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altasciences M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altasciences
What does Altasciences do?
Altasciences is an integrated early-phase contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology (Phase I to Phase II), bioanalysis, research support services, and manufacturing and analytical services under a single integrated Acceleration Platform that reduces program timelines by up to 40%.
Is Altasciences a public or private company?
Altasciences is a private company. It is classified as private equity controlled and is currently operating.
When was Altasciences founded?
Altasciences was founded in 1995. It employs 251 to 500 people.
Where is Altasciences based?
Altasciences is headquartered in Laval, Canada, in the North America region.
How does Altasciences make money?
Five revenue lines are on record. Preclinical Services are the primary driver. The others are clinical Research Services, bioanalytical Services, manufacturing and Analytical Services (CDMO) and research Support Services.
Who are Altasciences's main competitors?
Broad incumbents on record are WuXi AppTec, ICON plc, IQVIA, Syneos Health, Parexel and Labcorp (Covance). Direct peers are Worldwide Clinical Trials, Medpace, BioAgilytix Labs and Charles River Laboratories.
Does Altasciences have an API?
No public API is recorded for Altasciences.
What industry is Altasciences in?
Altasciences's product category is Contract Research Organization (CRO) and CDMO Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 5417 and its SIC code is 8731.